Artiva Biotherapeutics, Common Stock Cash And Equivalents
| ARTV Stock | 10.48 0.63 5.67% |
Artiva Biotherapeutics, Common fundamentals help investors to digest information that contributes to Artiva Biotherapeutics,'s financial success or failures. It also enables traders to predict the movement of Artiva Stock. The fundamental analysis module provides a way to measure Artiva Biotherapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Artiva Biotherapeutics, stock.
Artiva | Cash And Equivalents |
Artiva Biotherapeutics, Common Company Cash And Equivalents Analysis
Artiva Biotherapeutics,'s Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Artiva Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Artiva Biotherapeutics, is extremely important. It helps to project a fair market value of Artiva Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Artiva Biotherapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Artiva Biotherapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Artiva Biotherapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Artiva Biotherapeutics, Common has 0.0 in Cash And Equivalents. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.
Artiva Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Artiva Biotherapeutics,'s direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Artiva Biotherapeutics, could also be used in its relative valuation, which is a method of valuing Artiva Biotherapeutics, by comparing valuation metrics of similar companies.Artiva Biotherapeutics, is currently under evaluation in cash and equivalents category among its peers.
Artiva Fundamentals
| Return On Equity | -0.44 | ||||
| Operating Margin | (23.45) % | ||||
| Current Valuation | 138.19 M | ||||
| Shares Outstanding | 24.29 M | ||||
| Shares Owned By Insiders | 20.64 % | ||||
| Shares Owned By Institutions | 89.07 % | ||||
| Number Of Shares Shorted | 1.03 M | ||||
| Price To Book | 1.34 X | ||||
| Price To Sales | 103.75 X | ||||
| Revenue | 33.49 M | ||||
| EBITDA | (28.41 M) | ||||
| Net Income | (28.72 M) | ||||
| Total Debt | 16.91 M | ||||
| Book Value Per Share | 8.28 X | ||||
| Cash Flow From Operations | (47.43 M) | ||||
| Short Ratio | 20.47 X | ||||
| Earnings Per Share | (2.48) X | ||||
| Target Price | 21.25 | ||||
| Number Of Employees | 82 | ||||
| Market Capitalization | 269.85 M | ||||
| Total Asset | 105.11 M | ||||
| Retained Earnings | (181.31 M) | ||||
| Working Capital | 67.59 M | ||||
| Net Asset | 105.11 M |
About Artiva Biotherapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Artiva Biotherapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artiva Biotherapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artiva Biotherapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.